Contact us : info@bioworlde.com
Home > Product > Primary Antibodies
Cardiac Troponin I (TNNI3) polyclonal antibody BS78813
  • Western blot analysis of extracts of various cell lines, using Cardiac Troponin I antibody at 1:1000 dilution.
    Secondary antibody: HRP Goat Anti-Rabbit IgG at 1:10000 dilution.
    Lysates/proteins: 25ug per lane.
    Blocking buffer: 3% nonfat dry milk in TBST.
    Detection: ECL Basic Kit .
    Exposure time: 5s.
  • Immunofluorescence analysis of mouse heart cells using Cardiac Troponin I antibody at dilution of 1:100. Blue: DAPI for nuclear staining.
Product NameCardiac Troponin I (TNNI3) polyclonal antibody
Catalog No.BS78813
Swiss-ProtP19429
Host Rabbit
ReactivityHuman, Mouse, Rat
ApplicationsWB, IF/ICC
Application_allWB,1:500 - 1:2000|IF/ICC,1:50 - 1:200
BiowMW26kDa
Alternative NameTNNI3;CMD1FF;CMD2A;CMH7;RCM1;TNNC1;cTnI;troponin I3
Purification&PurityThe antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
ConjugateUnconjugated
ModificationUnmodification
Browse similar products>>
Size Price
50ul $208
100ul $358
Add to cart My orders
Product Name :
Cardiac Troponin I (TNNI3) polyclonal antibody
Background :
Troponin I (TnI), along with troponin T (TnT) and troponin C (TnC), is one of 3 subunits that form the troponin complex of the thin filaments of striated muscle. TnI is the inhibitory subunit; blocking actin-myosin interactions and thereby mediating striated muscle relaxation. The TnI subfamily contains three genes: TnI-skeletal-fast-twitch, TnI-skeletal-slow-twitch, and TnI-cardiac. This gene encodes the TnI-cardiac protein and is exclusively expressed in cardiac muscle tissues. Mutations in this gene cause familial hypertrophic cardiomyopathy type 7 (CMH7) and familial restrictive cardiomyopathy (RCM).
Product :
1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :
Unmodification
Immunogen :
Recombinant fusion protein of human Cardiac Troponin I (TNNI3)(NP_000354.4).
Conjugate :
Unconjugated
Modification :
Unmodification
  • Western blot analysis of extracts of various cell lines, using Cardiac Troponin I antibody at 1:1000 dilution.
    Secondary antibody: HRP Goat Anti-Rabbit IgG at 1:10000 dilution.
    Lysates/proteins: 25ug per lane.
    Blocking buffer: 3% nonfat dry milk in TBST.
    Detection: ECL Basic Kit .
    Exposure time: 5s.
  • Immunofluorescence analysis of mouse heart cells using Cardiac Troponin I antibody at dilution of 1:100. Blue: DAPI for nuclear staining.
Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.

Price/Size :

USD 368/1mg/vial



Tips: 

For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).

Describe :

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.

Formula:

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.

Storage:

The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C. 


Note :

This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.
COPYRIGHT © 2015-2018 Bioworld Technology, Inc. All rights reserved POLYCLONAL AND MONOCLONAL ANTIBODY CENTER